How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,463 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature Full Text available with Trip Pro

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature BACKGROUND DRESS is a rare, life threatening syndrome that occurs following exposure to certain medications, most commonly antibiotics and antiepileptics. While sulfonamide antibiotics are frequently implicated as causative agents for DRESS syndrome, furosemide, a nonantibiotic sulfonamide, has not been routinely reported as the causative agent despite its (...) . CONCLUSIONS We report a case of severe DRESS syndrome secondary to furosemide, only the second case report in medical literature implicating furosemide. Given its widespread use, the potentially life-threatening nature of DRESS syndrome and the commonly delayed time course in establishing the diagnosis, it is important to remember that, albeit rare, furosemide can be a cause of DRESS syndrome.

2018 The American journal of case reports

22. Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines

for medical necessity review , due to billing practices or claims that are not consistent with other providers in terms of frequency or some other manner. CPT ® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT ® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data (...) ), stereotactic radiosurgery (SRS) or intraoperative radiation therapy (IORT). Special physics consult, CPT ® code 77370, describes work performed by a qualified medical physicist to address a specific question or problem related to a complex radiation therapy plan. This only applies when the query to the physicist is beyond the scope of the routine physics work effort associated with radiation therapy planning and delivery. In response to a physician request, the physicist prepares a customized written

2018 AIM Specialty Health

23. Neuromuscular electrical stimulation as an adjunctive therapy to drotaverine hydrochloride for treating patients with diarrhea-predominant irritable bowel syndrome: A retrospective study. Full Text available with Trip Pro

Neuromuscular electrical stimulation as an adjunctive therapy to drotaverine hydrochloride for treating patients with diarrhea-predominant irritable bowel syndrome: A retrospective study. This retrospective study investigated the effectiveness and safety of neuromuscular electrical stimulation (NMES) as an adjunctive therapy to drotaverine hydrochloride (DHC) in patients with diarrhea-predominant irritable bowel syndrome (BP-IBS).A total of 108 patient cases with BP-IBS were included (...) in this study. Of these, 54 cases were assigned to a treatment group and received NMES and DHC, whereas the other 54 subjects were assigned to a control group and underwent DHC alone. All patients were treated for a total of 4 weeks. Primary outcomes were measured by the visual analog scale (VAS), and average weekly stool frequency. Secondary outcome was measured by the Bristol scale. In addition, adverse events were documented. All outcome measurements were analyzed before and after 4-week

2018 Medicine

24. Tuina (massage) therapy for diarrhea in COVID-19: a protocol for systematic review and meta-analysis

Tuina (massage) therapy for diarrhea in COVID-19: a protocol for systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2020 PROSPERO

25. Medications for the prevention and treatment of travellers' diarrhea. Full Text available with Trip Pro

Medications for the prevention and treatment of travellers' diarrhea. . Travellers' diarrhea (TD) remains one of the most common illnesses encountered by travellers to less developed areas of the world. Because bacterial pathogens such as enterotoxigenic Escherichia coli (ETEC), enteroaggregative E. coli , Campylobacter spp. and Shigella spp. are the most frequent causes, antibiotics have been useful in both prevention and treatment of TD.Results of trials that assessed the use of medications (...) for the prevention and treatment of TD were identified through PubMed and MEDLINE searches using search terms 'travellers' diarrhea', 'prevention' and 'treatment'. References of articles were also screened for additional relevant studies.Prevention of TD with antibiotics has been recommended only under special circumstances. Doxycycline, trimethoprim-sulfamethoxazole, fluoroquinolones and rifaximin have been used for prevention, but at present the first three antibiotics may have limited use secondary

2017 Journal of Travel Medicine

26. Appropriate prescribing of psychotropic medication for non-cognitive symptoms in people with dementia

that may occur following use of certain serotonergic medications. Symptoms can range from mild to severe and can include high body temperature, agitation, increased reflexes, tremor, sweating, dilated pupils, and diarrhoea. Selective serotonin A class of drugs that are typically used as antidepressants in the treatment reuptake inhibitor of major depressive disorder and anxiety disorders. Severe symptoms Symptoms that are very stressful and upsetting to the person with dementia; typically requires (...) Grading of Recommendations Assessment, Development and Evaluation GDG Guideline Development Group GDP Global Domestic Product MCI Mild Cognitive Impairment MHBC Ministry of Health British Columbia MHRA Medicines and Healthcare products Regulatory Agency NCEC National Clinical Effectiveness Committee NHMRC National Health and Medical Research Council NHS National Health Service NICE National Institute for Health and Care Excellence NPI Neuropsychiatric Inventory PBS Pharmaceutical Benefit Scheme PDD

2019 National Clinical Guidelines (Ireland)

27. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Full Text available with Trip Pro

within paediatric pain management. Non-steroidal anti-inflammatory drugs are currently licensed for use in Western countries, however they are not approved for infants under three months old. The main adverse effects include renal impairment and gastrointestinal issues. Common side effects in children include diarrhoea, headache, nausea, constipation, rash, dizziness, and abdominal pain.To assess the analgesic efficacy and adverse events of NSAIDs used to treat chronic non-cancer pain in children (...) % of aspirin participants (low-quality evidence). Secondary outcomesAll seven studies reported adverse events. Participants reporting an adverse event (one or more per person) by drug were: aspirin 85/202; fenoprofen 28/49; ibuprofen 40/45; indomethacin 9/30; ketoprofen 9/30; meloxicam 18/47; naproxen 44/202; and rofecoxib 47/209 (very low-quality evidence).All seven studies reported withdrawals due to adverse events. Participants withdrawn due to an adverse event by drug were: aspirin 16/120; celecoxib 10

2017 Cochrane

28. Diarrhoea - adult's assessment: Scenario: Chronic diarrhoea ( 4weeks)

than functional disorder). Fever, tachycardia, hypotension, dehydration. Look for other features suggestive of an underlying , including: Travel abroad — consider an infective cause, especially Giardia . Laxative use (including for treatment of hepatic encephalopathy). Other drugs. For examples, see the section on . Recent use of an antibiotic or proton pump inhibitor is associated with Clostridium difficile infection. Chronic fatty diarrhoea — suggests fat maldigestion (for example pancreatic (...) -cut irritable bowel syndrome in primary or secondary care [ ]. Faecal occult blood testing This recommendation is based on the NICE quality standard for suspected cancer that suggests adults presenting in primary care with symptoms that suggest colorectal cancer, who do not meet the referral pathway criteria, have a test for blood in their faeces [ ]. The BSG Guidelines for the investigation of chronic diarrhoea in adults discuss two types of faecal occult blood test: the older faecal occult blood

2020 NICE Clinical Knowledge Summaries

29. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations

. Methods An Expert Panel was convened to update clinical practice guideline recommendations based on a systematic review of the medical literature. Recommendations For patients with high PD-L1 expression (TPS$ 50%) and nonsquamous cell carcinoma (non-SCC), in the absence of contraindications to immune checkpoint therapies, treatment options include: Recommendation1.1. ForpatientswithhighPD-L1expression(TPS$50%),non-SCC,andperformancestatus(PS)0to1, clinicians should offer single-agent pembrolizumab (...) , andPS0 to1,andwhohave contraindicationstoordeclineimmunotherapy, cliniciansshouldoffer standardchemotherapy with platinum-based two-drug combinations as outlined in the 2015 update (Type: evidence based; Evidence quality: high; Strength of recommendation: strong). Recommendation 2.5. For patients with negative (TPS 0%) and low positive (TPS 1% to 49%) PD-L1 expression, non-SCC, andPS0to1,andwhohavecontraindicationstoordeclineimmunotherapyandnotdeemedcandidatesforplatinum-based therapy

2020 Cancer Care Ontario

30. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

effectiveness 16 Costs in the model 21 Cost-effectiveness results 22 Innovation 24 Discount rate 24 End of life 25 Cancer Drugs Fund 26 Other factors 27 4 Implementation 29 5 Appraisal committee members and NICE project team 30 Appraisal committee members 30 NICE project team 30 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559) © NICE 2019. All rights reserved. Subject to Notice of rights (https (...) ://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 311 1 Recommendations Recommendations 1.1 Axicabtagene ciloleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed. 1.2 This recommendation is not intended to affect both treatment in preparation

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

31. Is diarrhea an adverse event of the second generation of hormonal therapy in castration resistant prostate cancer? Data from a literature based meta-analysis

Is diarrhea an adverse event of the second generation of hormonal therapy in castration resistant prostate cancer? Data from a literature based meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) . Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital

2019 PROSPERO

32. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy MASCC=ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy Rajesh V. Lalla, DDS, PhD 1 ; Joanne Bowen, PhD 2 ; Andrei Barasch, DMD, MDSc 3 ; Linda Elting, PhD 4 ; Joel Epstein, DMD, MSD 5 ; Dorothy M. Keefe, MD 2 ; Deborah B. McGuire, PhD, RN 6 ; Cesar Migliorati, DDS, MS, PhD 7 ; Ourania Nicolatou-Galitis, DDS, MSc, DrDent 8 ; Douglas E. Peterson, DMD (...) mucositis in patients receiving H&NRT. No guideline was possible regarding theuseoforalcareprotocolsforthetreatmentoforalmuco- sitis. In addition, no guideline was possible related to the individualuseofthefollowingmouthrinses:saline,sodium bicarbonate, mixed medication mouthwashes, calcium phosphate, and chlorhexidine in patients receiving chemo- therapy,duetoinadequateand=orconflictingevidence. 31 Growth factors and cytokines To the best of our knowledge, palifermin (keratinocyte growthfactor-1

2014 International Society for Oral Oncology

33. Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome

Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03457324 Recruitment Status

2018 Clinical Trials

34. Traditional Chinese medicine for treating antibiotic-associated diarrhea (AAD): a systematic review and meta-analysis

Traditional Chinese medicine for treating antibiotic-associated diarrhea (AAD): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler

2020 PROSPERO

35. Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea

16. In patients with BAD and recurrent or worsening symptoms despite stable BAST , diagnostic re-evaluation should be conducted. Designated a good practice statement Statement 17. In patients being considered for BAST , a review of concurrent medications should be conducted to minimize the potential for drug interactions. Designated a good practice statement Statements with no recommendations No recommendation A. In patients with chronic diarrhea including IBS-D and functional diarrhea (...) ) was withdrawn, and the drug was prescribed again at the dose that controlled the patient’s symptoms (7). Only 6% of patients were able to discontinue therapy without suffering recurrent diarrhea. Discussion Evidence suggests that some patients with BAD will require regular daily dosing, whereas others may be able to discon- tinue completely or use on-demand therapy for symptom control. The dose or frequency of BAST required to control symptoms may be dependent on the severity of symptoms, underlying causes

2020 Canadian Association of Gastroenterology

36. Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients Full Text available with Trip Pro

Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients The aim was to evaluate the effects of traditional Chinese medicine (TCM) as a combination medication with adjuvant chemotherapy on postoperative early stage non-small cell lung cancer (NSCLC) patients. The 314 patients with completely resected stage IB, II or IIIA cancers were assigned into vinorelbine plus cisplatin/carboplatin (NP/NC) (control, n = 158) and NP/NC (...) with additional TCM (intervention, n = 156) groups. The primary endpoint was QOL scores; secondary endpoints were the toxicity and safety of the regimens. The NP/NC regimen caused mild (grade 1 or 2) non-hematologic toxic effects in the patients comprising vomiting (43.6%), fatigue (36.9%), pain (23%), dry mouth (27.6%) and diarrhea (7.9%). The incidence of adverse events was significantly lower in the intervention group than in the control group (0.57% vs 4.02%, P = 0.037). Transient severe (grade 3 or 4

2017 Scientific reports Controlled trial quality: uncertain

37. Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine.

Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine. Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine. (aCTIVE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2017 Clinical Trials

38. Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis

dose. Week 2 to Week 14: SC injection of tralokinumab maintenance dose. CYP substrates - non-investigational medicinal products: Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg. Drug: Tralokinumab Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation (...) Frame: From Day 1 up to Week 30 ] Presence of anti-drug antibodies (yes/no) [ Time Frame: From Day 1 up to Week 30 ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout

2018 Clinical Trials

39. Emerging Drugs for Duchenne Muscular Dystrophy

regulatory approval, a major barrier to the uptake of novel therapies for DMD is likely to be cost. Furthermore, there is the possibility for some of the medications to be used in combination, which will increase the cost further. Criteria will need to be determined to establish which patients are more likely to benefit, and to identify when a drug is no longer beneficial. Administering medication to children can be challenging. Idebenone and ataluren are orally administered and require multiple daily (...) and mortality. DMD is caused by a mutation of the dystrophin gene that results in a lack of dystrophin, a protein that is necessary for muscle cell function. The mainstays of current therapy to treat DMD are corticosteroids and assistive devices. This bulletin focuses on new and emerging drugs for DMD with completed phase IIb or phase III trials and includes ataluren (nonsense mutation suppression), eteplirsen (exon 51 skipping), and idebenone (adenosine triphosphate [ATP] modulation). Ezutromid (utrophin

2017 CADTH - Issues in Emerging Health Technologies

40. Emerging Drugs for Duchenne Muscular Dystrophy

regulatory approval, a major barrier to the uptake of novel therapies for DMD is likely to be cost. Furthermore, there is the possibility for some of the medications to be used in combination, which will increase the cost further. Criteria will need to be determined to establish which patients are more likely to benefit, and to identify when a drug is no longer beneficial. Administering medication to children can be challenging. Idebenone and ataluren are orally administered and require multiple daily (...) and mortality. DMD is caused by a mutation of the dystrophin gene that results in a lack of dystrophin, a protein that is necessary for muscle cell function. The mainstays of current therapy to treat DMD are corticosteroids and assistive devices. This bulletin focuses on new and emerging drugs for DMD with completed phase IIb or phase III trials and includes ataluren (nonsense mutation suppression), eteplirsen (exon 51 skipping), and idebenone (adenosine triphosphate [ATP] modulation). Ezutromid (utrophin

2017 CADTH - Issues in Emerging Health Technologies

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>